JP2016511257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511257A5 JP2016511257A5 JP2015560312A JP2015560312A JP2016511257A5 JP 2016511257 A5 JP2016511257 A5 JP 2016511257A5 JP 2015560312 A JP2015560312 A JP 2015560312A JP 2015560312 A JP2015560312 A JP 2015560312A JP 2016511257 A5 JP2016511257 A5 JP 2016511257A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- item
- composition
- dna damaging
- damaging agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770802P | 2013-02-28 | 2013-02-28 | |
| US61/770,802 | 2013-02-28 | ||
| US201361892854P | 2013-10-18 | 2013-10-18 | |
| US61/892,854 | 2013-10-18 | ||
| PCT/US2014/019034 WO2014134311A1 (en) | 2013-02-28 | 2014-02-27 | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016511257A JP2016511257A (ja) | 2016-04-14 |
| JP2016511257A5 true JP2016511257A5 (cg-RX-API-DMAC10.html) | 2017-06-15 |
Family
ID=51428806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560312A Pending JP2016511257A (ja) | 2013-02-28 | 2014-02-27 | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140356383A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2961424A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016511257A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20150122730A (cg-RX-API-DMAC10.html) |
| CN (1) | CN105142664A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2902757A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW201444577A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014134311A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY173390A (en) | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
| HRP20191690T1 (hr) * | 2012-04-27 | 2019-12-27 | Millennium Pharmaceuticals, Inc. | Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| WO2024027815A1 (zh) | 2022-08-05 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 特异性结合gucy2c和cd3的抗原结合分子及其医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274861B1 (en) * | 2000-03-27 | 2009-12-23 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells |
| EP2370098A4 (en) * | 2008-12-03 | 2013-07-17 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| MY173390A (en) * | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
-
2014
- 2014-02-27 JP JP2015560312A patent/JP2016511257A/ja active Pending
- 2014-02-27 KR KR1020157026431A patent/KR20150122730A/ko not_active Withdrawn
- 2014-02-27 WO PCT/US2014/019034 patent/WO2014134311A1/en not_active Ceased
- 2014-02-27 EP EP14756404.1A patent/EP2961424A4/en not_active Withdrawn
- 2014-02-27 US US14/192,632 patent/US20140356383A1/en not_active Abandoned
- 2014-02-27 CN CN201480023899.7A patent/CN105142664A/zh active Pending
- 2014-02-27 CA CA2902757A patent/CA2902757A1/en not_active Abandoned
- 2014-02-27 TW TW103106933A patent/TW201444577A/zh unknown